Table 3 Association of EGFR gene alterations with clinicopathological parameters
From: Epidermal growth factor receptor structural alterations in gastric cancer
Clinicopathological parameters | EGFR status | |||
|---|---|---|---|---|
Amplification/mutation (n = 6) | Normal (n = 24) | Total (n = 30) | p value | |
Sex (F/M) | 1/5 | 10/14 | 11/19 | 0.2557 |
Age (SD) | 62.3 ± 14,1 | 56.3 ± 16.8 | 57.5 ± 16.2 | 0.4271 |
Tumour localization | 0.8548 | |||
Proximal | 3 | 11 | 14 | |
Distal | 3 | 13 | 16 | |
Size (SD) | 11.6 ± 9.8 | 5.8 ± 2.0 | 6.9 ± 5.0 | *0.0094 |
Lauren's classification | 0.1261 | |||
Intestinal | 1 | 12 | 13 | |
Diffuse | 5 | 9 | 14 | |
Atypical | 0 | 3 | 3 | |
Wall penetration | 0.4642 | |||
Early (T1) | 0 | 2 | 2 | |
Advanced (T2-T4) | 6 | 22 | 28 | |
Vascular Invasion | 0.7125 | |||
Absent (N0) | 3 | 14 | 17 | |
Present (N = 1) | 3 | 10 | 13 | |
Lymph node metastasis | 0.1921 | |||
Absent | 1 | 11 | 12 | |
Present | 5 | 13 | 18 | |
Staging | 0.3845 | |||
I | 1 | 7 | 8 | |
II | 0 | 5 | 5 | |
III | 5 | 11 | 16 | |
IV | 0 | 1 | 1 | |